SPLENOTIR: Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura
Study Details
Study Description
Brief Summary
The aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with ITP who had a splenectomy to treat their ITP(Immune thrombocytopenic purpura).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Immune thrombocytopenic purpura (ITP) is a rare autoimmune thrombocytopenia whose incidence is 2 to 5 cases / 100,000 inhabitants / year. The potentially serious haemorrhagic risk is the major issue of management. A recent international consensus conference classifies PTI according to the duration of thrombocytopenia: acute ITP (<3 months), persistent ITP (3-12 months) and chronic ITP (> 12 months) (Rodeghiero 2009). In the acute or persistent phase, polyvalent immunoglobulins (IVIG) and / or corticosteroids are proposed. In the chronic phase, splenectomy is a possible cure for 70% of patients. No predictor of treatment response is known.
The pathophysiology of ITP is multifactorial: platelet phagocytosis, mediated by autoantibody, macrophages of the reticuloendothelial system, and destruction in the spleen, genetic background and / or environmental factor favoring the role of certain lymphocyte subpopulations, cytotoxic or regulatory T, via their cytokine environment, abnormalities of thrombopoiesis.
At present, no predictive factor of splenectomy success has been identified. The aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with ITP who had a splenectomy to treat their ITP.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| ITP group On frozen spleens of already splenectomized adult ITP patients. |
Procedure: Immunolabeling
Immunolabeling of abnormalities observed by the cell study in flow cytometry.
|
| Control group On frozen control spleens from patients who had a splenectomy at the Bordeaux University Hospital following a road accident. |
Procedure: Immunolabeling
Immunolabeling of abnormalities observed by the cell study in flow cytometry.
|
Outcome Measures
Primary Outcome Measures
- Complete remission (CR) after splenectomy. [At the inclusion]
Determination of ITP status following Rodeghiero criteria : complete remission if platelet count > 100 G/L. patient who is not on complete remission after splenectomy will be considered to be failing.
Eligibility Criteria
Criteria
Inclusion Criteria:
- The analyzed spleens belong to the collection of biological samples declared to the ministry by the Laboratory of Pathology of Haut-Lévêque Hospital (Dr Parrens).
Exclusion Criteria:
- Opposition of the patient.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University Hospital, Bordeaux
Investigators
- Principal Investigator: Jean-François VIALLARD, Pr, University Hospital, Bordeaux
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHU BX 2011/05